Search hospitals
>
New York
>
New York
Icahn School of Medicine at Mount Sinai
Claim this profile
New York, New York 10029
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Solid Tumors
Conducts research for Breast Cancer
Conducts research for Multiple Myeloma
1544 reported clinical trials
158 medical researchers
Summary
Icahn School of Medicine at Mount Sinai is a medical facility located in New York, New York. This center is recognized for care of Cancer, Lung Cancer, Solid Tumors, Breast Cancer, Multiple Myeloma and other specialties. Icahn School of Medicine at Mount Sinai is involved with conducting 1,544 clinical trials across 1,437 conditions. There are 158 research doctors associated with this hospital, such as Edward J. Kim, Matthew Galsky, M.D., Deborah Doroshow, MD, PhD, and Thomas Marron, MD PhD.
Area of expertise
Cancer
Icahn School of Medicine at Mount Sinai has run 149 trials for Cancer. Some of their research focus areas include:
Lung Cancer
Icahn School of Medicine at Mount Sinai has run 58 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Edward J. Kim
University of California Davis Comprehensive Cancer Center
2 years of reported clinical research
Matthew Galsky, M.D.
Icahn School of Medicine at Mount Sinai
6 years of reported clinical research
Deborah Doroshow, MD, PhD
Mount Sinai Hospital
5 years of reported clinical research
Thomas Marron, MD PhD
Icahn School of Medicine at Mount Sinai
3 years of reported clinical research
Clinical Trials running at Icahn School of Medicine at Mount Sinai
Crohn's Disease
Breast Cancer
Cancer
Ovarian Cancer
Pompe Disease
Inflammatory Bowel Disease
Prostate Cancer
Asthma
Ulcerative Colitis
Fallopian Tube Cancer
Vedolizumab Post-Stem Cell Transplant
for Crohn's Disease
Crohn's Disease (CD) is an inflammatory bowel disease. It can lead to significant complications and discomfort in the stomach and intestines. Crohn's disease is a debilitating, incurable disease of immune cells; it affects almost 1 million people in the United States. CD is characterized by inflammation of the stomach and intestine as well as organs outside of the intestines such as the skin, eyes, and joints. Current therapies to treat CD aim to suppress the patient's immune cells but these therapies become ineffective for the majority of patients and lead to complications including the requirement for surgical bowel resection, impaired quality of life, and lifelong disability. Hematopoietic stem cell transplantation (HCT) is a procedure used to treat a number of medical conditions including Crohn's disease. To improve success of HCT in CD doctors considered combining transplant with other drugs to improve the chances of achieving remission and also maintaining the remission. The Investigators' plan in this study is to incorporate the drug Vedolizumab after transplant to test if this drug will improve remission and make patients healthier. Patients may qualify to take part in this research study because Crohn's disease is active, because surgery is not a treatment option and because there is evidence that the disease has failed to respond to treatments for Crohn's disease including the following: * corticosteroids * azathioprine, 6-mercaptopurine, methotrexate * Anti-TNFα (infliximab, adalimumab, certolizumab, golimumab) * Anti-integrin agents (natalizumab, Vedolizumab) If patients meet entry criteria will undergo a baseline endoscopy, colonoscopy and MR or CT enterography. If documentation of active mucosal disease patients will then be tapered off of current medications and undergo stem cell mobilization. Mobilization will involve low dose chemotherapy, growth factors and require 1-2 week hospitalization. Patients will then undergo stem cell transplant which will involve high dose chemotherapy and require a 2-4 week hospitalization. After restoration of the immune system patients will be placed on vedolizumab per standard dosing (0,2,6 then 8 every weeks) for a total of 8 doses. Patients will have monthly study visits and a repeat colonoscopy and MR/CT scan at 6 months.
Recruiting
3 awards
Phase 2
Risankizumab
for Pediatric Crohn's Disease
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies. Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1(including Sub-cohort 1A) will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 118 pediatric participants with CD will be enrolled at around 100 sites worldwide. Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Recruiting
2 awards
Phase 3
Mirikizumab
for Ulcerative Colitis
This trial is testing a medication called mirikizumab to see if it can help children with ulcerative colitis or Crohn's disease by reducing inflammation in their digestive tracts.
Recruiting
2 awards
Phase 3
3 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Icahn School of Medicine at Mount Sinai?
Icahn School of Medicine at Mount Sinai is a medical facility located in New York, New York. This center is recognized for care of Cancer, Lung Cancer, Solid Tumors, Breast Cancer, Multiple Myeloma and other specialties. Icahn School of Medicine at Mount Sinai is involved with conducting 1,544 clinical trials across 1,437 conditions. There are 158 research doctors associated with this hospital, such as Edward J. Kim, Matthew Galsky, M.D., Deborah Doroshow, MD, PhD, and Thomas Marron, MD PhD.
Where is Icahn School of Medicine at Mount Sinai located?
The Icahn School of Medicine at Mount Sinai is situated in Manhattan, New York, nestled on the Upper East Side between Fifth and Madison Avenues, covering East 98th to 102nd Streets. Accessible by subway line number 6 and bus lines M1, M2, M3, M4, M96, M98, M101, M102, M103, M106. For comprehensive public transit details, visit the Metropolitan Transportation Authority (MTA) website.
Who should I call to ask about financial aid or insurance network?
**Financial Assistance at Icahn School of Medicine at Mount Sinai:** - **Department of Patient Financial Services:** For financial assistance applications and eligibility inquiries, contact (212) 731-3100 or visit One Gustave L. Levy Place, Box 6000, New York, New York 10029. **Insurance Inquiries:** - **Customer Service Billing Office:** For insurance and billing questions, call (212) 987-3100, Monday-Friday, 8 am – 6 pm. - **Mount Sinai Doctors Faculty Practice:** Participates in most insurance plans, including Medicare. Verify acceptance and discuss requirements by contacting the physician's office or your insurance company directly.
What insurance does Icahn School of Medicine at Mount Sinai accept?
The Icahn School of Medicine at Mount Sinai, part of the Mount Sinai Health System, participates in numerous health plan networks. It's important to verify that both the hospital and the physicians involved in your care accept your insurance plan. For detailed information on physician insurance participation, use the "Find a Doctor" feature at www.mountsinai.org, and for hospital-specific insurance information, direct inquiries to the respective departments or visit the hospital's website.
What awards or recognition has Icahn School of Medicine at Mount Sinai received?
The Icahn School of Medicine at Mount Sinai has been awarded a five-year, $55.5 million Clinical and Translational Science Award by the National Center for Advancing Translational Sciences, part of the NIH. This funding supports ConduITS, the Institute for Translational Sciences at Mount Sinai, enhancing its role in the CTSA Program, which includes 63 nationwide sites. It will boost Mount Sinai's capabilities in translational research informatics, digital health, and data science, accelerating research translation into discoveries for improved health outcomes across diverse populations.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.